

TAMING RANDOM CONJUGATION


A GENERAL APPROACH FOR 1-TO-1 LINKAGE OF PROTEINS AND PAYLOADS

Sasha Koniev, CEO




New chimeric anticancer therapeutics

PIPELINE OF PROPRIETARY AND COLLABORATION PROGRAMS (2+2)



(1) Equimolar native chemical tagging




GET PREVIOUSLY INACCESSIBLE 1:1 CHIMERAS

USE OFF-THE-SHELF PROTEIN SUBSTRATES





GMP READY SCALABLE PROCESS

NBE THROUGH A ONE-STEP MANUFACTURE


10kDa






Lysozyme




100kDa





HSA



1mDa




IgG



So what?

ADC:

- 5 being marketed
- 56 in clinical development
- Main hurdles: resistance, modest efficacy in solid tumours



Drug-to-antibody ratio (DAR):
number of drug molecules per antibody

RESISTANCE

Combination of drugs with complementary mechanisms

SOLID TUMOURS

Lower DAR = deeper penetration
(ideally – DAR1)

Achievable with ENACT

SEEKING INDUSTRIAL & ACADEMIC PARTNERS:

- Evaluating DAR1 and combo ADC *vs* classic ADC
- Exploring new chimeric therapeutics
- Flexible business model:
 - co-development (sharing risks/costs)
 - target-by-target out-licensing

TECHNOLOGY RÉSUMÉ:

- Protein-payload 1:1 fusion
- Applicable to the off-the-shelf proteins
- Scalable and GMP-ready

APPLICATIONS:

- Combo-payload ADC
- DAR1 ADC
- New chimeric formats

Email ok@syndivia.com
for details